We’re pleased to announce the successful enrolment of 40 out of 60 patients in our IRB approved clinical trial for diabetic nerve pain.The multi-arm, head-to-head trial will evaluate the efficacy and tolerability of our proprietary medicinal cannabis product against a multi-billion dollar big pharmaceutical company drug.Half of all people with diabetes will develop neuropathy which can be incredibly challenging and impact a person’s quality of life. We expect to complete trial enrolment and provide a trial read out in Q4 2022.Read more: http://ow.ly/OY8x50KJMXK
ZLD Price at posting:
$1.47 Sentiment: Buy Disclosure: Held
